Search for: "Lane v. Lane" Results 3061 - 3080 of 3,455
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
10 Dec 2007, 4:38 pm
Box 22501 Eugene, OR 97402 Phone: (541) 689-7242 (V/TTY) Fax: (541) 461-8601 E-mail: kswezey@efn.org Web: http://www.shhhor.org Programs for Children and Youth who are Deaf or Hard of Hearing Deaf and Hard of Hearing Access Program Orego [read post]
9 Nov 2007, 8:01 am
The following is a list of ficilaties for indivudals with cerebral palsy or other special needs in Connecticut. [read post]
28 Apr 2008, 11:00 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: CAFC vacates FTC’s decision that Rambus breached antitrust duty by violating JEDEC patent disclosure rules and orders new trial: (Philip Brooks), (Techdirt), (Ars Technica), (IP Law360), (Peter Zura's 271 Patent Blog), (Hal Wegner), (IPBiz), (IP Law360), UK Court of Appeal rules on whether prior art not in the same design field… [read post]
18 May 2018, 8:02 am by John Elwood
Last up is Wright v. [read post]
12 Dec 2021, 10:36 am by Eric Goldman
Given these results, these cases once again remind Section 230 critics that Section 230 is a procedural fast lane to the inevitable outcomes. [read post]
14 Jun 2015, 4:09 pm by INFORRM
Events 1 July 2015: “Bird & Bird’s Annual Data Protection Update” Bird & Bird, 15 Fetter Lane, London Please let us know if there are any events you would like to be included on this list by email: inforrmeditorial@gmail.com. [read post]
21 Oct 2015, 9:44 am by Benjamin Wittes
— Anne-Marie Slaughter (@SlaughterAM) October 17, 2015 Putin v. [read post]
15 Aug 2022, 9:28 am by privacylawyer
There is a case from Ontario called R. v. [read post]
7 Feb 2020, 12:43 am
Topics will include, amongst others: the implications of non-obviousness for follow-on medical innovation (e.g. drug repurposing) after the UK Supreme Court's 2019 decision in Actavis v ICOS; the current and future roles of competition law in controlling drug prices, including an update on Flynn and Pfizer; and the potential effect of Brexit on the trade of medical products. [read post]